biote Corp
NASDAQ:BTMD
biote Corp
biote Corp. is a woman-led company, which engages in providing bio identical hormone pellet therapy. The company is headquartered in Irving, Texas. The company went IPO on 2021-03-02. The firm provides components to enable Biote-certified practitioners to establish, build, and implement a program designed to optimize hormone levels using personalized solutions for their patient populations. Its Biote Method is a comprehensive, end-to-end practice-building platform that provides Biote-certified practitioners with components specifically developed for practitioners in the hormone optimization space, such as Biote Method education, training and certification, practice management software, inventory management software, and information regarding available hormone replacement therapy (HRT) products, as well as digital and point-of-care marketing support. The firm trains practitioners how to identify and treat early indicators of hormone-related aging conditions. The company also sells a complementary Biote-branded line of dietary supplements.
biote Corp. is a woman-led company, which engages in providing bio identical hormone pellet therapy. The company is headquartered in Irving, Texas. The company went IPO on 2021-03-02. The firm provides components to enable Biote-certified practitioners to establish, build, and implement a program designed to optimize hormone levels using personalized solutions for their patient populations. Its Biote Method is a comprehensive, end-to-end practice-building platform that provides Biote-certified practitioners with components specifically developed for practitioners in the hormone optimization space, such as Biote Method education, training and certification, practice management software, inventory management software, and information regarding available hormone replacement therapy (HRT) products, as well as digital and point-of-care marketing support. The firm trains practitioners how to identify and treat early indicators of hormone-related aging conditions. The company also sells a complementary Biote-branded line of dietary supplements.
Revenue Decline: Biote reported Q3 revenue of $48 million, down 6.7% year-over-year, mainly due to lower procedure revenue.
Procedure Revenue Down: Procedure revenue fell 10.4% due to slower clinic additions and higher attrition following commercial team restructuring.
Supplements Growth: Dietary supplements revenue increased 8.4% to $11.2 million, driven by e-commerce, and is expected to grow at a mid-teens rate for the full year.
Margins Improved: Gross margin rose to 71.8%, up 150 basis points, helped by cost savings from manufacturing integration.
Profitability Lower: Net income was $9.2 million and EPS was $0.22, both down from last year. Adjusted EBITDA fell 20.5% to $12.9 million.
Sales Team Rebuild: Commercial team rebuild is about 75–85% complete, with full headcount targeted by year-end and a 3–6 month ramp-up for new hires.
Guidance Reiterated: 2025 revenue guidance remains above $190 million and adjusted EBITDA above $50 million.
Share Repurchases & Settlements: Company repurchased about 1 million shares and settled payment obligations with the Donovitz family at a substantial cash savings.
